News

From predicting viral outbreaks via fungal spores and combating drug-resistant gonorrhea to advancing fungal detection through genomic sequencing and improving antiviral resistance testing for vulnerable patients, and more.

César de la Fuente, PhD, provides insights on the promising work of his lab as they accelerate the speed of finding new antimicrobial molecules.

At ASM Microbe 2025, Pelumi Oladipo discusses E marmotae’s reduced motility, misidentification as E coli, and the diagnostic tools closing the gap.

This comes after the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) made the recommendation to remove the vaccine preservative.

New research reveals accelerated brain aging in healthy adults during the COVID-19 pandemic, highlighting broader neurological and social effects.

In the largest world study, there was a 98% reduction in hospitalizations of babies who received the RSV vaccine compared with those who did not receive the RSV vaccine.

Lin Zhu explains why testing alone will not achieve HCV elimination without better access and integrated care.

In the second installment of our Media Day interview, Temple University Hospital’s Rafik Samuel, MD, talks about what he has experienced as a clinician seeing patients with HIV before there were treatments available as well as his approach with fellows in teaching them about this disease.

CDC reports 11 people sick across 10 states with Salmonella linked to frozen sprouted beans causing diarrhea, fever, and severe illness in vulnerable groups.

Rafik Samuel, MD, chief of the Section of Infectious Disease at Temple University Hospital and professor of medicine at Lewis Katz School of Medicine at Temple University, talks about its history and the uniqueness of its fellowship program.

Presented at ASM Microbe, Pelumi Oladipo's study identifies the first North American human case of E marmotae infection and introduces methods to improve species-level diagnosis.

First author Jacek Skarbinski, MD, offers insights on new data published last week showing how this population can benefit from continued vaccination.

The most successful FMT approach involved administering multiple-dose capsules or colonoscopy following an extended course of antibiotic pretreatment.

Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP) talks about how his team developed a test to identify fungi, and how they utilize it to diagnose, make treatment adjustments, and rule out hospital acquired infections.

Jason Haukoos, MD, on how the DETECT Hep C trial leverages 24/7 emergency care to reach vulnerable patients.

Margie Lee, DVM, MS, PhD, wants young researchers and providers to know that despite the current environment, this is not the first time science has had to deal with a challenges to research and funding.

Edward Weinstein, MD of Pfizer, says longer courses may benefit severely immunocompromised patients, even without major gains in viral suppression.

Cases and deaths in the state are down from the 2 previous years. Here are some clinical considerations, treatment options, and prevention strategies in relation to these infections.

This week, the first US study screening hepatitis B and D concurrently found that 2.2% of HBV-positive samples had HDV antibodies, the FDA approved GSK’s Shingrix, and more.

Luisa M Stamm, MD, PhD, further discusses MK-8527 and islatravir-based regimens in HIV research.

In the second installment of our conversation with Jeremy Faust, MD, he addresses the uncertainty surrounding guidance and where to turn for information.

New evidence-based recommendations prioritize timely, targeted therapy and a symptom-focused classification to optimize treatment outcomes and antimicrobial stewardship.

At IAS 2025, ViiV’s Jean van Wyk, MBChB, MFPM, shares how real-world data and patient priorities are guiding a new era of HIV care.

A large study looked at booster uptake and effectiveness among US adults who received chemotherapy or immunotherapy.

New format eliminates reconstitution step, offering greater convenience for providers and supporting expanded access for at-risk adults.

New research finds no link between aluminum in vaccines and autism, asthma, or other health conditions, strengthening the case for vaccine safety.

Jeremy Faust, MD, discusses what he and other providers are dealing with in the face of conflicting guidance and actions from the federal agencies.

Jason Haukoos, MD, MSc, FACEP, shares the decade-long journey behind the DETECT Hep C trial and why emergency departments are key to implementing Centers for Disease Control and Prevention screening guidelines.

The designation is for the company’s TXA14007, its investigational antibiotic to be studied in combination with levofloxacin.